Altimmune, Inc. (ALT)
After hours:
| Previous close | 6.55 |
| Open | 6.63 |
| Bid | 7.03 x 300 |
| Ask | 7.08 x 1400 |
| Day's range | 6.55 - 7.39 |
| 52-week range | 2.09 - 14.84 |
| Volume | |
| Avg. volume | 4,706,808 |
| Market cap | 501.23M |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.66 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Jan 2017 |
| 1y target est | 21.86 |
GlobeNewswireAltimmune to Participate at Two Upcoming Conferences
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern Time GLP-1-Based Therapeutics Summit (Philadelphia, PA) Title: Focusing on the
- GlobeNewswire
Altimmune Statement on the Passing of Dr. Stephen Harrison
GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing. Dr. Harrison’s countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were o
- GlobeNewswire
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in anon-steatotic model of liver fibrosis Cash, cash equivalents and short-term investments of $198.0 million at December 31, 2023 Webcast to be held to
